NL-OMON32748已完成不适用
A phase 1 double blind, placebo controlled study of ALX-0141 single dose subcutaneous administration in healthy post-menopausal women - ALX-0141 s.c. SAD study
Ablynx N.V.0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy post menopausal women, 18 - 80 years old, BMI between 18 and 36 kg/m2, moderate or non-smoker.
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.0 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
1 期
A clinical phase I study on GIC-1001 in healthy volunteersGastroenterology/pain management/management of visceral pain during sedation-free colonoscopyDigestive SystemISRCTN09480239gIcare Pharma Inc (Canada)80
招募中
1 期
A Study to Evaluate the Safety of a Single and Multiple Oral Doses of a Biologic Therapy (MB-001) or placebo in Healthy Human Participantslcerative colitisOral and Gastrointestinal - Inflammatory bowel diseaseUlcerative colitisACTRN12624000524594Mage Biologics48
进行中（未招募）
1 期
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-DKAstraZeneca AB90
进行中（未招募）
不适用
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaChronic obstructive pulmonary disease and Sputum EosinophiliaMedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020127-52-DEAstraZeneca AB90
进行中（未招募）
1 期
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-GBAstraZeneca AB101